ChloroquineV1, PubMed, Curation, bibRecord, 000200

Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.

Identifieur interne : 000200 ( PubMed/Curation ); précédent : 000199; suivant : 000201

Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.

Auteurs : Fei Yu [États-Unis] ; Jing Li [États-Unis] ; Ying Xie [États-Unis] ; Richard L. Sleightholm [États-Unis] ; David Oupick [République populaire de Chine]

Source :

Journal of controlled release : official journal of the Controlled Release Society [ 1873-4995 ] ; 2016.

RBID : pubmed:27473763

Descripteurs français

KwdFr :
- Animaux, Antinéoplasiques (), Antinéoplasiques (administration et posologie), Antinéoplasiques (usage thérapeutique), Autophagie (), Chimiokine CXCL12 (pharmacologie), Chloroquine (), Chloroquine (administration et posologie), Chloroquine (usage thérapeutique), Extracellular Signal-Regulated MAP Kinases (métabolisme), Femelle, Humains, Lignée cellulaire tumorale, Mouvement cellulaire (), Polymères (), Polymères (administration et posologie), Récepteurs CXCR4 (antagonistes et inhibiteurs), Récepteurs CXCR4 (métabolisme), Souris de lignée BALB C, Survie cellulaire (), Systèmes de délivrance de médicaments, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (traitement médicamenteux).
MESH :
- administration et posologie : Antinéoplasiques, Chloroquine, Polymères.
- anatomopathologie : Tumeurs du poumon.
- antagonistes et inhibiteurs : Récepteurs CXCR4.
- métabolisme : Extracellular Signal-Regulated MAP Kinases, Récepteurs CXCR4.
- pharmacologie : Chimiokine CXCL12.
- traitement médicamenteux : Tumeurs du poumon.
- usage thérapeutique : Antinéoplasiques, Chloroquine.
- Animaux, Antinéoplasiques, Autophagie, Chloroquine, Femelle, Humains, Lignée cellulaire tumorale, Mouvement cellulaire, Polymères, Souris de lignée BALB C, Survie cellulaire, Systèmes de délivrance de médicaments.

English descriptors

KwdEn :
- Animals, Antineoplastic Agents (administration & dosage), Antineoplastic Agents (chemistry), Antineoplastic Agents (therapeutic use), Autophagy (drug effects), Cell Line, Tumor, Cell Movement (drug effects), Cell Survival (drug effects), Chemokine CXCL12 (pharmacology), Chloroquine (administration & dosage), Chloroquine (chemistry), Chloroquine (therapeutic use), Drug Delivery Systems, Extracellular Signal-Regulated MAP Kinases (metabolism), Female, Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (pathology), Mice, Inbred BALB C, Polymers (administration & dosage), Polymers (chemistry), Receptors, CXCR4 (antagonists & inhibitors), Receptors, CXCR4 (metabolism).
MESH :
- chemical , administration & dosage : Antineoplastic Agents, Chloroquine, Polymers.
- chemical , antagonists & inhibitors : Receptors, CXCR4.
- chemical , chemistry : Antineoplastic Agents, Chloroquine, Polymers.
- chemical , metabolism : Extracellular Signal-Regulated MAP Kinases, Receptors, CXCR4.
- chemical , pharmacology : Chemokine CXCL12.
- chemical , therapeutic use : Antineoplastic Agents, Chloroquine.
- drug effects : Autophagy, Cell Movement, Cell Survival.
- drug therapy : Lung Neoplasms.
- pathology : Lung Neoplasms.
- Animals, Cell Line, Tumor, Drug Delivery Systems, Female, Humans, Mice, Inbred BALB C.

Abstract

Chloroquine (CQ) is a widely used antimalarial drug with emerging potential in anticancer therapies due to its apparent inhibitory effects on CXCR4 chemokine receptor, autophagy, and cholesterol metabolism. This study reports on polymeric CQ (pCQ) as a macromolecular drug with antimetastatic activity. The pCQ polymers were synthesized by copolymerization of methacryloylated hydroxy-CQ (HCQ) and N-(2-hydroxypropyl)methacrylamide (HPMA). The results show that pCQ is significantly more effective in inhibiting cancer cell migration and invasion when compared with the parent HCQ. The proposed mechanism of action at least partially relies on the ability of pCQ to inhibit cell migration mediated by the CXCR4/CXCL12 pathway. The pCQ also demonstrates superior inhibitory activity over HCQ when tested in a mouse model of experimental lung metastasis. Lastly, pCQ shows the ability to efficiently translocate to the cytoplasm while exhibiting lower cytotoxicity than HCQ. Overall, this study supports pCQ as a promising polymeric drug platform suitable for use in combination antimetastatic strategies and potential use in cytoplasmic drug delivery.

DOI: 10.1016/j.jconrel.2016.07.040
PubMed: 27473763

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000200

Links to Exploration step

pubmed:27473763

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.</title>
<author><name sortKey="Yu, Fei" sort="Yu, Fei" uniqKey="Yu F" first="Fei" last="Yu">Fei Yu</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Jing" sort="Li, Jing" uniqKey="Li J" first="Jing" last="Li">Jing Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Xie, Ying" sort="Xie, Ying" uniqKey="Xie Y" first="Ying" last="Xie">Ying Xie</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sleightholm, Richard L" sort="Sleightholm, Richard L" uniqKey="Sleightholm R" first="Richard L" last="Sleightholm">Richard L. Sleightholm</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Oupick, David" sort="Oupick, David" uniqKey="Oupick D" first="David" last="Oupick">David Oupick</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing, China. Electronic address: david.oupicky@unmc.edu.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27473763</idno>
<idno type="pmid">27473763</idno>
<idno type="doi">10.1016/j.jconrel.2016.07.040</idno>
<idno type="wicri:Area/PubMed/Corpus">000200</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000200</idno>
<idno type="wicri:Area/PubMed/Curation">000200</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000200</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.</title>
<author><name sortKey="Yu, Fei" sort="Yu, Fei" uniqKey="Yu F" first="Fei" last="Yu">Fei Yu</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Jing" sort="Li, Jing" uniqKey="Li J" first="Jing" last="Li">Jing Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Xie, Ying" sort="Xie, Ying" uniqKey="Xie Y" first="Ying" last="Xie">Ying Xie</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Sleightholm, Richard L" sort="Sleightholm, Richard L" uniqKey="Sleightholm R" first="Richard L" last="Sleightholm">Richard L. Sleightholm</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Oupick, David" sort="Oupick, David" uniqKey="Oupick D" first="David" last="Oupick">David Oupick</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing, China. Electronic address: david.oupicky@unmc.edu.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of controlled release : official journal of the Controlled Release Society</title>
<idno type="eISSN">1873-4995</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antineoplastic Agents (administration & dosage)</term>
<term>Antineoplastic Agents (chemistry)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Autophagy (drug effects)</term>
<term>Cell Line, Tumor</term>
<term>Cell Movement (drug effects)</term>
<term>Cell Survival (drug effects)</term>
<term>Chemokine CXCL12 (pharmacology)</term>
<term>Chloroquine (administration & dosage)</term>
<term>Chloroquine (chemistry)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Drug Delivery Systems</term>
<term>Extracellular Signal-Regulated MAP Kinases (metabolism)</term>
<term>Female</term>
<term>Humans</term>
<term>Lung Neoplasms (drug therapy)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Mice, Inbred BALB C</term>
<term>Polymers (administration & dosage)</term>
<term>Polymers (chemistry)</term>
<term>Receptors, CXCR4 (antagonists & inhibitors)</term>
<term>Receptors, CXCR4 (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antinéoplasiques ()</term>
<term>Antinéoplasiques (administration et posologie)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Autophagie ()</term>
<term>Chimiokine CXCL12 (pharmacologie)</term>
<term>Chloroquine ()</term>
<term>Chloroquine (administration et posologie)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Extracellular Signal-Regulated MAP Kinases (métabolisme)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Mouvement cellulaire ()</term>
<term>Polymères ()</term>
<term>Polymères (administration et posologie)</term>
<term>Récepteurs CXCR4 (antagonistes et inhibiteurs)</term>
<term>Récepteurs CXCR4 (métabolisme)</term>
<term>Souris de lignée BALB C</term>
<term>Survie cellulaire ()</term>
<term>Systèmes de délivrance de médicaments</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Chloroquine</term>
<term>Polymers</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, CXCR4</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Chloroquine</term>
<term>Polymers</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Extracellular Signal-Regulated MAP Kinases</term>
<term>Receptors, CXCR4</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Chemokine CXCL12</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Chloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Chloroquine</term>
<term>Polymères</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs CXCR4</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Autophagy</term>
<term>Cell Movement</term>
<term>Cell Survival</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Extracellular Signal-Regulated MAP Kinases</term>
<term>Récepteurs CXCR4</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Chimiokine CXCL12</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Chloroquine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Drug Delivery Systems</term>
<term>Female</term>
<term>Humans</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Antinéoplasiques</term>
<term>Autophagie</term>
<term>Chloroquine</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Mouvement cellulaire</term>
<term>Polymères</term>
<term>Souris de lignée BALB C</term>
<term>Survie cellulaire</term>
<term>Systèmes de délivrance de médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Chloroquine (CQ) is a widely used antimalarial drug with emerging potential in anticancer therapies due to its apparent inhibitory effects on CXCR4 chemokine receptor, autophagy, and cholesterol metabolism. This study reports on polymeric CQ (pCQ) as a macromolecular drug with antimetastatic activity. The pCQ polymers were synthesized by copolymerization of methacryloylated hydroxy-CQ (HCQ) and N-(2-hydroxypropyl)methacrylamide (HPMA). The results show that pCQ is significantly more effective in inhibiting cancer cell migration and invasion when compared with the parent HCQ. The proposed mechanism of action at least partially relies on the ability of pCQ to inhibit cell migration mediated by the CXCR4/CXCL12 pathway. The pCQ also demonstrates superior inhibitory activity over HCQ when tested in a mouse model of experimental lung metastasis. Lastly, pCQ shows the ability to efficiently translocate to the cytoplasm while exhibiting lower cytotoxicity than HCQ. Overall, this study supports pCQ as a promising polymeric drug platform suitable for use in combination antimetastatic strategies and potential use in cytoplasmic drug delivery.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27473763</PMID>
<DateCompleted><Year>2018</Year>
<Month>01</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4995</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>244</Volume>
<Issue>Pt B</Issue>
<PubDate><Year>2016</Year>
<Month>12</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>Journal of controlled release : official journal of the Controlled Release Society</Title>
<ISOAbbreviation>J Control Release</ISOAbbreviation>
</Journal>
<ArticleTitle>Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.</ArticleTitle>
<Pagination><MedlinePgn>347-356</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0168-3659(16)30484-9</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jconrel.2016.07.040</ELocationID>
<Abstract><AbstractText>Chloroquine (CQ) is a widely used antimalarial drug with emerging potential in anticancer therapies due to its apparent inhibitory effects on CXCR4 chemokine receptor, autophagy, and cholesterol metabolism. This study reports on polymeric CQ (pCQ) as a macromolecular drug with antimetastatic activity. The pCQ polymers were synthesized by copolymerization of methacryloylated hydroxy-CQ (HCQ) and N-(2-hydroxypropyl)methacrylamide (HPMA). The results show that pCQ is significantly more effective in inhibiting cancer cell migration and invasion when compared with the parent HCQ. The proposed mechanism of action at least partially relies on the ability of pCQ to inhibit cell migration mediated by the CXCR4/CXCL12 pathway. The pCQ also demonstrates superior inhibitory activity over HCQ when tested in a mouse model of experimental lung metastasis. Lastly, pCQ shows the ability to efficiently translocate to the cytoplasm while exhibiting lower cytotoxicity than HCQ. Overall, this study supports pCQ as a promising polymeric drug platform suitable for use in combination antimetastatic strategies and potential use in cytoplasmic drug delivery.</AbstractText>
<CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Fei</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xie</LastName>
<ForeName>Ying</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sleightholm</LastName>
<ForeName>Richard L</ForeName>
<Initials>RL</Initials>
<AffiliationInfo><Affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Oupický</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pharmaceutical Sciences, China Pharmaceutical University, Nanjing, China. Electronic address: david.oupicky@unmc.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R21 EB019175</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 GM106397</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 CA036727</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB015216</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 EB020308</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>07</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>J Control Release</MedlineTA>
<NlmUniqueID>8607908</NlmUniqueID>
<ISSNLinking>0168-3659</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011108">Polymers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber>
<NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">CXCR4</Keyword>
<Keyword MajorTopicYN="Y">Chloroquine</Keyword>
<Keyword MajorTopicYN="Y">Endosomal release</Keyword>
<Keyword MajorTopicYN="Y">HPMA</Keyword>
<Keyword MajorTopicYN="Y">Metastasis</Keyword>
<Keyword MajorTopicYN="Y">Polymeric drug</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>04</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>07</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>07</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>1</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27473763</ArticleId>
<ArticleId IdType="pii">S0168-3659(16)30484-9</ArticleId>
<ArticleId IdType="doi">10.1016/j.jconrel.2016.07.040</ArticleId>
<ArticleId IdType="pmc">PMC5167664</ArticleId>
<ArticleId IdType="mid">NIHMS808934</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Biol Chem. 2001 Apr 27;276(17):14153-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11154697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2009 Apr;9(4):239-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19279573</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 18;319(1):12-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15158435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2010 Feb 5;140(3):313-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20144757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Pharm. 2012 Sep 4;9(9):2380-402</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22844998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2009 Dec 25;625(1-3):220-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19836374</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Chem Biomol Eng. 2010;1:149-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22432577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Physiol Biochem. 2016;38(5):2030-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27160165</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1982 Dec;79(23):7302-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6760194</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2011 Sep;10(9):1533-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21878654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):182-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26677873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2003 Jun 19;22(25):3927-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12813466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Sep 30;8(9):e74216</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24098639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thorac Cardiovasc Surg. 2012 Nov;144(5):1167-1175.e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22925564</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2004 Oct 19;99(3):435-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15451601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2008 Sep 10;130(2):183-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18585414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomaterials. 2014 Nov;35(33):9144-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25109439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2008 Dec 15;14(24):7975-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19088012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2006 Nov 2;49(22):6522-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17064070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Angew Chem Int Ed Engl. 2012 Oct 15;51(42):10472-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22952048</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2015 Sep 5;762:472-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25959387</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2007 Apr 1;109(7):2708-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17119115</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2011 May 10;151(3):220-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21078351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2015 Jan;125(1):42-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25654549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Biochem. 1986;55:663-700</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2874766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2013 Jan;65(1):49-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23123294</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2015 Oct 1;21(19):4278-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26199389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(2):e31004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22319600</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AAPS J. 2009 Mar;11(1):13-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19125334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2006 Jul;10 (1):51-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16843265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2005 Sep;5(9):726-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16148885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2006 Feb 21;110(3):595-604</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16377019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2014 Jul;13(7):1758-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24785258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2009 Nov 12;61(13):1121-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19682515</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2013 Aug 10;169(3):276-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23379996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 1998 Jun;54(1):39-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9741902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oncogene. 2016 Aug 25;35(34):4518-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26853465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Cancer Res. 2010 Jun 1;16(11):2927-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20484021</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autophagy. 2012 Feb 1;8(2):200-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22252008</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Clin Oncol. 2011 May 17;8(9):528-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21587219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Cancer. 2006 Mar 27;94(6):863-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16495919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>ACS Macro Lett. 2016 Mar 15;5(3):342-345</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27795873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2010 Aug 3;145(3):182-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20226220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Angew Chem Int Ed Engl. 2006 Apr 3;45(15):2348-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16557636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2013 Jan;65(1):60-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22981753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2015 Dec 10;219:369-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26410809</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2006 Mar 1;107(5):1761-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16269611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2014 Sep 28;190:371-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24818766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Control Release. 2011 May 30;152(1):110-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21352876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2013 Jan 1;73(1):3-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23288916</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000200 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000200 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:27473763
   |texte=   Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:27473763" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.

Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki